Sakar Healthcare Ltd

Sakar Healthcare Limited was incorporated as a Private company under the name 'Sakar Healthcare Private Limited on 26th March 2004. Subsequently, the Company became a Public Limited Company on March 27, 2015 and changed to 'Sakar Healthcare Limited. The Company is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections and Oral Solid Dossages. In 2005, the Company started commercial production for Plant - 1 which was established for production of Liquid Orals; in 2007, it started exporting its products overseas; started commercial production for Plant - 2 which was established for production of Beta Lactum Tablet and Capsules and Dry Syrup B-lactum. / Sachet in 2008. Further, it started commercial production for Plant - 3 which was established for production of Liquid Injectibles (SVP) - Ampoules and Liquid Injectibles (SVP) - Vials. In 2012, it started commercial production for Plant - 4 which was established for production of Dry Powder Injection. In 2017, it started Lyophilised injection product commercialisation. In 2020, the Company received EU GMP certification for SVP unit manufacturing liquid and Lyophilised injections. In 2021, the Oncology Unit started operations in Bavla location. In 2022-23, the Company started commercialization with Oncology product post receiving WHO GMP certification. The Company granted a patent for IMATINIB and the EU GMP certification and began oncology unit to export oncology products in FY 2025. The Company focused on oncology products with the launch of oncology molecules, increasing regulatory filings and marketing authorizations and a growing network of international partnerships in 2026. It shared 250 oncology dossiers with partners and prospective markets worldwide of which 12 dossiers received Marketing Authorizations from regulatory authorities in 2026.